Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Elena Nikulina
Elena Nikulina

Arvinas doses first patient in clinical trial for HPK1 PROTAC degrader

Arvinas doses first patient in clinical trial for HPK1 PROTAC degrader
Arvinas begins HPK1 trial dosing

Arvinas announced it has dosed the first patient in its Phase 1/2 clinical trial evaluating an investigational HPK1 PROTAC degrader.

This marks an early-stage milestone for Arvinas as it explores the potential of targeted protein degradation in cancer therapy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

From PlayStation to crypto: Why Sony is building its own blockchain
  • By Ksenia Gerey
  • 4 hours ago
From PlayStation to crypto: Why Sony is building its own blockchain
Editors' Picks
Google loses billions: What’s behind Alphabet’s stock crash?
  • By Oleg Tkachenko
  • 6 hours ago
Google loses billions: What’s behind Alphabet’s stock crash?
Editors' Picks
The end of Bitcoin’s growth era: Why prominent investors doubt its future
  • By Olena Litvinenko
  • Yesterday
The end of Bitcoin’s growth era: Why prominent investors doubt its future
Editors' Picks
All Editors' Top Picks

Latest Arvinas News

Arvinas introduces Early Career Researcher Award with 25000 grant for targeted protein degradation
  • By Elena Nikulina
  • Yesterday
Arvinas introduces Early Career Researcher Award with 25000 grant for targeted protein degradation
Companies
#Arvinas
First PROTAC protein degrader approval advances targeted protein degradation, Arvinas states
  • By Ksenia Gerey
  • 19.10.2026
First PROTAC protein degrader approval advances targeted protein degradation, Arvinas states
Companies
#Arvinas
Arvinas presents new oculomotor and biomarker data from Phase 1 trial in Parkinson Disease
  • By Oksana Koneva
  • 07.10.2026
Arvinas presents new oculomotor and biomarker data from Phase 1 trial in Parkinson Disease
Companies
#Arvinas
All Arvinas News
  • Ksenia Gerey
  • 4 hours ago
From PlayStation to crypto: Why Sony is building its own blockchain
  • Oleg Tkachenko
  • 6 hours ago
Google loses billions: What’s behind Alphabet’s stock crash?
  • Olena Litvinenko
  • Yesterday
The end of Bitcoin’s growth era: Why prominent investors doubt its future
  • Eugene Komchuk
  • Yesterday
WeFi CEO: Banks are overstating the threat from stablecoins
  • Dmytro Kharkov
  • Yesterday
HSBC’s warning signs point to a bigger risk for global banks
  • Igor Krasulya
  • 10 min ago
Stanley Druckenmiller focuses his debut tweet on Hyperliquid, Luke Martin notes
  • Mykhailo Ihnatenko
  • 10 min ago
PWR backlog rises 19 percent quarter over quarter, Stephanie Link notes
  • Daria Chernytska
  • 13 min ago
Micron price prediction: Phil Rosen sees $1,700 target in 18 months as bears are challenged
  • Elena Nikulina
  • 15 min ago
Diane Swonk: Real GDP rises on consumer spending and federal outlays
  • Eugene Komchuk
  • 30 min ago
Market catalyst outlook for 2027 analyzed during interview, Craig Shapiro discusses
Top News
  • Eugene Komchuk
  • 15 min ago
Christine Lagarde announces early resignation as ECB president
Christine Lagarde announces early resignation as ECB president
  • Olga Shendetskaya
  • 1 hour ago
Brent drops below $110 as Middle East peace talks ease supply concerns
Brent drops below $110 as Middle East peace talks ease supply concerns
  • Andrey Mastykin
  • 1 hour ago
Nasdaq futures decline as Alphabet sparks tech selloff
Nasdaq futures decline as Alphabet sparks tech selloff
  • Olga Shendetskaya
  • 4 hours ago
ECB set to hold rates despite inflation and French bond market turmoil
ECB set to hold rates despite inflation and French bond market turmoil
  • Ivan Andriyenko
  • 5 hours ago
Gold approaches $4,000 as investors assess Fed rate outlook
Gold approaches $4,000 as investors assess Fed rate outlook
Live News
  • Anton Kharitonov
  • Now
EUR/USD remains in a strong downtrend as ECB decision approaches
  • Jose Antonio Gastelum
  • Now
Cardano Foundation expands role in Swiss tokenized securities market
  • Mykhailo Ihnatenko
  • Now
Nvidia stock faces $210 risk as Alphabet earnings shake AI sentiment
  • Pavlo Kot
  • Now
Visa stablecoin settlement volume surges tenfold to $25 billion
  • Mykhailo Ihnatenko
  • Now
Ethereum price faces $2,200 risk as early holder activity and ETF outflows weigh
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers